# | Title | Journal | Year | Citations |
---|
1 | Platelet size | Blood Coagulation and Fibrinolysis | 1996 | 646 |
2 | Multi-centre investigation on reference ranges for ROTEM thromboelastometry | Blood Coagulation and Fibrinolysis | 2005 | 441 |
3 | Statistica for Windows | Blood Coagulation and Fibrinolysis | 1995 | 351 |
4 | Thrombelastography | Blood Coagulation and Fibrinolysis | 2001 | 273 |
5 | Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran | Blood Coagulation and Fibrinolysis | 2012 | 248 |
6 | The platelet glycoprotein Ib???IX complex | Blood Coagulation and Fibrinolysis | 1994 | 238 |
7 | Platelet size: measurement, physiology and vascular disease | Blood Coagulation and Fibrinolysis | 1996 | 238 |
8 | Prevention of venous thromboembolism in medical patients with enoxaparin | Blood Coagulation and Fibrinolysis | 2003 | 224 |
9 | Clinical experience with recombinant factor VIIa | Blood Coagulation and Fibrinolysis | 1998 | 205 |
10 | Plasminogen | Blood Coagulation and Fibrinolysis | 1992 | 200 |
11 | Antithrombin | Blood Coagulation and Fibrinolysis | 2002 | 191 |
12 | Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis | Blood Coagulation and Fibrinolysis | 2003 | 167 |
13 | Update on von Willebrand factor multimers | Blood Coagulation and Fibrinolysis | 2014 | 166 |
14 | Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis | Blood Coagulation and Fibrinolysis | 1999 | 157 |
15 | The effect of recombinant factor VIIa (NovoSeven???) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0 | Blood Coagulation and Fibrinolysis | 1998 | 155 |
16 | The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects | Blood Coagulation and Fibrinolysis | 1994 | 153 |
17 | Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery | Blood Coagulation and Fibrinolysis | 2000 | 151 |
18 | Stability of coagulation proteins in frozen plasma | Blood Coagulation and Fibrinolysis | 2001 | 150 |
19 | Effects of serotonin on platelet activation in whole blood | Blood Coagulation and Fibrinolysis | 1997 | 146 |
20 | The effects of alcohol on coagulation and fibrinolytic factors | Blood Coagulation and Fibrinolysis | 1998 | 144 |
21 | NovoSeven® as a universal haemostatic agent | Blood Coagulation and Fibrinolysis | 2000 | 140 |
22 | Tissue factor pathway inhibitor and the current concept of blood coagulation | Blood Coagulation and Fibrinolysis | 1995 | 133 |
23 | Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications | Blood Coagulation and Fibrinolysis | 2002 | 128 |
24 | Thrombin structure and function | Blood Coagulation and Fibrinolysis | 1991 | 127 |
25 | Effect of fibrin structure on plasmin-mediated dissolution of plasma clots | Blood Coagulation and Fibrinolysis | 1995 | 126 |
26 | A murine model of factor XI deficiency | Blood Coagulation and Fibrinolysis | 1997 | 126 |
27 | Venous and arterial thrombosis following administration of intravenous immunoglobulins | Blood Coagulation and Fibrinolysis | 2005 | 124 |
28 | Factor VIIa in the treatment of haemophilia | Blood Coagulation and Fibrinolysis | 1990 | 121 |
29 | Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? | Blood Coagulation and Fibrinolysis | 2000 | 115 |
30 | A comparison of the Thrombelastograph and the ROTEM | Blood Coagulation and Fibrinolysis | 2007 | 113 |
31 | Platelets, coagulation, and fibrinolysis in sickle cell disease | Blood Coagulation and Fibrinolysis | 1991 | 110 |
32 | Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation | Blood Coagulation and Fibrinolysis | 2003 | 109 |
33 | Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation | Blood Coagulation and Fibrinolysis | 2009 | 108 |
34 | Hereditary deficiency of antithrombin III, protein C and protein S | Blood Coagulation and Fibrinolysis | 1992 | 106 |
35 | Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia | Blood Coagulation and Fibrinolysis | 1997 | 106 |
36 | Long-term prophylaxis in von Willebrand disease | Blood Coagulation and Fibrinolysis | 2005 | 106 |
37 | Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty | Blood Coagulation and Fibrinolysis | 2014 | 103 |
38 | Thromboelastography with citrated blood | Blood Coagulation and Fibrinolysis | 2004 | 102 |
39 | Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura | Blood Coagulation and Fibrinolysis | 2006 | 102 |
40 | Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy | Blood Coagulation and Fibrinolysis | 2006 | 102 |
41 | What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies | Blood Coagulation and Fibrinolysis | 2019 | 101 |
42 | Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry | Blood Coagulation and Fibrinolysis | 1994 | 100 |
43 | Transmission of a procoagulant signal from tissue factor-bearing cells to platelets | Blood Coagulation and Fibrinolysis | 1996 | 100 |
44 | Thromboelastography: a reliable test? | Blood Coagulation and Fibrinolysis | 2001 | 99 |
45 | Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography | Blood Coagulation and Fibrinolysis | 2007 | 98 |
46 | The present status of tissue factor pathway inhibitor | Blood Coagulation and Fibrinolysis | 1992 | 97 |
47 | Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment | Blood Coagulation and Fibrinolysis | 1996 | 97 |
48 | International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients | Blood Coagulation and Fibrinolysis | 2006 | 97 |
49 | Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing??s syndrome | Blood Coagulation and Fibrinolysis | 1999 | 96 |
50 | Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale | Blood Coagulation and Fibrinolysis | 2003 | 95 |